August 8, 2022

Medical Trend

Medical News and Medical Resources

Russian COVID-19 vaccines with 91.8% effective on seniors

Russian COVID-19 vaccines with 91.8% effective on seniors

 

Russian COVID-19 vaccines with 91.8% effective on seniors.  The protective power of the elderly reaches 91.8%, and the interim results of the Russian COVID-19 vaccine phase 3 clinical trial are released.

On February 2, “The Lancet” released the interim results obtained in the Phase 3 clinical trial of the COVID-19 vaccine Sputnik V developed in Russia. The data comes from 19,866 participants, of whom approximately three-quarters (14,964) received two doses of the vaccine, and one-quarter (4902) received a placebo. In the vaccine group, 21 days after the first dose of vaccination, 16 participants were diagnosed as symptomatic cases of new coronavirus pneumonia, while 62 people in the placebo group were diagnosed. It can be concluded that the effective rate of the vaccine is 91.6%.

Russian COVID-19 vaccines with 91.8% effective on seniors

In the trial, there were 2144 volunteers over 60 years old. The effectiveness of the vaccine in this age group was 91.8%. No serious side effects that may be related to Sputnik V were reported. The study also found that the vaccine has a 100% preventive effect on moderate or severe new coronavirus disease.

The accumulation of differences in COVID-19 patients after the first dose of vaccine

Russian COVID-19 vaccines with 91.8% effective on seniors

21 days after the first dose of vaccination, there were no reports of severe or moderate new coronavirus pneumonia in the vaccine group, and 20 cases in the placebo group.

The IFN-γ response of vaccinated subjects was significantly increased, showing that it stimulated a cellular immune response

Russian COVID-19 vaccines with 91.8% effective on seniors

Studies have shown that serious adverse events related to vaccines are rare, less than 0.2% of vaccine recipients. The main side effects that have been reported are mild side effects, such as injection pain, flu-like symptoms, and fatigue.

Kirill Dmitriev, director of the Russian Direct Investment Fund (RDIF), which is responsible for the foreign sales of the vaccine, said that Russia has already shared Phase III clinical trial data with regulatory agencies in some countries and has started Submit it to the European Medicines Agency (EMA) for approval.

  • The Sputnik V vaccine has been authorized in more than ten countries;
  • These include the former Soviet Republic of Belarus, Armenia and Turkmenistan;
  • Latin American countries include Argentina, Bolivia and Venezuela;
  • Some African countries as well as Serbia, Iran, Palestine and the UAE.

(source:internet, reference only)


Disclaimer of medicaltrend.org